Roivant Sciences (ROIV) Operating Income (2020 - 2026)
Roivant Sciences' (ROIV) quarterly Operating Income came in at -$930.3 million in Q4 2025, down 29.51% YoY from -$1.3 billion in Q4 2024, and down 203.79% on a QoQ basis from -$306.2 million in Q3 2025.
Roivant Sciences (ROIV) Operating Income (2020 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 6 years of Operating Income data on file, last reported at -$930.3 million in Q4 2025.
- Quarterly Operating Income fell 29.51% year-over-year to -$930.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$2.2 billion (down 156.49% YoY) and the FY2026 annual result came in at -$515.1 million, up 48.66% from the prior year.
- Operating Income declined to -$930.3 million in Q4 2025, from -$306.2 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of $5.1 billion in Q4 2023 to a low of -$1.1 billion in Q4 2021.
- A 5-year average of -$98.3 million and a median of -$284.9 million in 2025 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2021 — Operating Income plunged 337.22% — and 2023, when it jumped 644.81%.
- Tracing ROIV's Operating Income over 5 years: stood at -$1.1 billion in 2021, then grew by 13.25% to -$941.2 million in 2022, then jumped by 644.81% to $5.1 billion in 2023, then tumbled by 114.01% to -$718.3 million in 2024, then fell by 29.51% to -$930.3 million in 2025.
- The last three Operating Income figures came in at -$930.3 million (Q4 2025), -$306.2 million (Q3 2025), and -$284.9 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -365.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -365.99 Mn |
| Dec 31, 2025 | -930.31 Mn |
| Sep 30, 2025 | -306.23 Mn |
| Jun 30, 2025 | -284.92 Mn |
| Dec 31, 2024 | -718.33 Mn |
| Sep 30, 2024 | -341.71 Mn |
| Jun 30, 2024 | -102.24 Mn |
| Dec 31, 2023 | 5.13 Bn |
| Sep 30, 2023 | -213.89 Mn |
| Jun 30, 2023 | -276.41 Mn |
| Dec 31, 2022 | -941.15 Mn |
| Sep 30, 2022 | -280.77 Mn |
| Jun 30, 2022 | -282.31 Mn |
| Dec 31, 2021 | -1.08 Bn |
| Sep 30, 2021 | -684.43 Mn |
| Jun 30, 2021 | -154.39 Mn |
| Dec 31, 2020 | -259.07 Mn |
| Sep 30, 2020 | -156.54 Mn |
| Jun 30, 2020 | -114.45 Mn |